Enrollment complete
A Phase 3, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT No.: NCT06212999
Study Type: INTERVENTIONAL
Phase:
Phase III
Region: California - Northern
Acronym: STOP-HS LTE
Official Title
A Phase 3, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Purpose
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT05620836\]).
Detailed Description
Eligibility Criteria
Inclusion Criteria
|
• Completion of the study treatment period of the originating parent study (INCB 54707-301 or INCB 54707-302).
• Agreement to use contraception.
• Willing and able to comply with the study protocol and procedures.
• Further inclusion criteria apply.
|
Exclusion Criteria
|
• Participation in the extension study could expose the participant to an undue safety risk.
• Women who are pregnant (or who are considering pregnancy) or breastfeeding.
• Further exclusion criteria apply.
|
Keywords and/or Specific Medical Conditions
|
|
|
|
|
|
|
|
|
|
- Long-Term Extension (LTE)
|
|
|
|
|
Sponsors
|